Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

References

• Abilify Maintena (aripiprazole monohydrate extended-release injectable) [prescribing information]. Otsuka America Pharmaceutical, Incorporated; 7 2017.
   Google Scholar
• Aristada (aripiprazole monohydrate extended-release injectable) [prescribing information]. Alkermes, Incorporated; 9 2017.
   Google Scholar
• Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheumatol. 1990;33:91–94. doi:10.1002/art.1780330112
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Thompson AM, Carmody T, Bugno R, Erwin T. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007;58:844–847. doi:10.1176/ps.2007.58.6.84417535946
   PubMed Web of Science ®Google Scholar
• Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delago A. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165–171. doi:10.2147/PPA.S1533721573047
   PubMed Web of Science ®Google Scholar
• Dammerman R, Kim S, Adera M, Schwarz A. Pharmacokinetics and safety of risperidone subcutaneous implants in stable patients with schizophrenia. Clin Pharmacol Drug Develop. 2018;7(3):298–310. doi:10.1002/cpdd.428
   PubMed Web of Science ®Google Scholar
• Glazer W, Maynard C, Berkman S. Injection site leakage of depot neuroleptics: intramuscular versus subcutaneous injection. J Clin Psychiatry. 1987;48(6):237–239.3584079
   PubMed Web of Science ®Google Scholar
• Glazer WM. Who receives long-acting antipsychotic medications? Psychiatry Serv. 2007;58:437. doi:10.1176/ps.2007.58.4.437
   PubMed Web of Science ®Google Scholar
• Gomeni R, Heidbreder C, Fudala PJ, Nasser AF. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting sustained-release formulation of risperidone. J Clin Pharmacol. 2013;53(10):1010–1019. doi:10.1002/jcph.14123868656
   PubMed Web of Science ®Google Scholar
• Haldol Decanoate (haloperidol decanoate long-acting injection) [prescribing information]. Janssen Pharmaceuticals, Incorporated; 3 2017.
   Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–282. doi:10.1097/YIC.0b013e3280c2842417690596
   PubMed Web of Science ®Google Scholar
• Invega Sustenna (paliperidone palmitate extended-release injectable) [prescribing information]. Janssen Pharmaceuticals, Incorporated; 7 2017.
   Google Scholar
• Invega Trinza (paliperidone palmitate extended-release injectable) [prescribing information]. Janssen Pharmaceuticals, Incorporated; 3 2017.
   Google Scholar
• Ivaturi V, Gopalakrishnan M, Gobburu J, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol. 2017;83(7):1476–1498. doi:10.1111/bcp.v83.728133766
   PubMed Web of Science ®Google Scholar
• Isitt J, Nadipelli R, Kouassi A, Fava M, Heidbreder C. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016;174(1–3):126–131. doi:10.1016/j.schres.2016.03.02027066860
   PubMed Web of Science ®Google Scholar
• Jin J, Zhu L, Chen M, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923–941. doi:10.2147/PPA.S8727126170642
   PubMed Web of Science ®Google Scholar
• Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845–1849.8308768
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115–1124. doi:10.4088/JCP.10r06264yel20923620
   PubMed Web of Science ®Google Scholar
• Kane J, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:63–67. doi:10.1192/bjp.195.52.s63
   PubMedGoogle Scholar
• Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol. 2015;55(1):93–103. doi:10.1002/jcph.v55.125043337
   PubMed Web of Science ®Google Scholar
• Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014;53(6):533–543. doi:10.1007/s40262-014-0132-724464285
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; steering committee on practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(S2):1–56.
   Google Scholar
• Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140. doi:10.1097/JCP.000000000000047926862829
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management. Alden Press UK. Edn. London: The British Psychological Society and the Royal College of Psychiatrists; 2014.
   Google Scholar
• Olfson M, Mechanic D, Hansell S, Boyer CV, Walkup J. Prediction of homelessness within three months of discharge among inpatients with schizophrenia. Psychiatry Serv. 1999;50:667–673. doi:10.1176/ps.50.5.667
   PubMed Web of Science ®Google Scholar
• Patel M, David A. Why aren’t depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatric Treat. 2005;11:203–213. doi:10.1192/apt.11.3.203
   Google Scholar
• Patel MX, de Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009;23:789–796. doi:10.1177/026988110809212418583438
   PubMed Web of Science ®Google Scholar
• Perseris (risperidone) [package insert]. North Chesterfield (VA): Indivior, Incorporated; 2018.
   Google Scholar
• Prolixin (fluphenazine decanoate Injection) [prescribing information]. West-Ward Pharmaceuticals Corporation; 10 2017.
   Google Scholar
• Risperdal Consta (risperidone microspheres long-acting injectable) [prescribing information]. Janssen Pharmaceuticals, Incorporated; 2 2017.
   Google Scholar
• Spratt D, Stewart I, Savage C, et al. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017;102(7):2349–2355. doi:10.1210/jc.2017-0035928379417
   PubMed Web of Science ®Google Scholar
• Svedberg B, Backenroth-Ohsako G, Lützén K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs. 2003;12:110–118. doi:10.1046/j.1440-0979.2003.00277.x12956022
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Maddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–609. doi:10.1176/appi.ajp.2011.1008122421362741
   PubMed Web of Science ®Google Scholar
• Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S43–S50. doi:10.1192/bjp.195.52.s4319880916
   PubMedGoogle Scholar
• Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70:1397–1406. doi:10.4088/JCP.09m05284yel19906343
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152:408–414. doi:10.1016/j.schres.2013.08.00123972821
   PubMed Web of Science ®Google Scholar
• Zyprexa Relprevv (olanzapine pamoate long-acting injection) [prescribing information]. Eli Lilly and Company; 7 2017.
   Google Scholar
• Soliman E, Ranjan S, Xu T, et al. A narrative review of the success of intramuscular gluteal injections and its impact in psychiatry. Bio-Design Manuf. 2018;1(3):161–170. doi:10.1007/s42242-018-0018-x
   PubMed Web of Science ®Google Scholar
• Chan VO, Colville J, Persaud T, Buckley O, Hamilton S, Torreggiani WC. Intramuscular injections into the buttocks: are they truly intramuscular? Eur J Radiol. 2006;58(3):480–484. doi:10.1016/j.ejrad.2006.01.00816495027
   PubMed Web of Science ®Google Scholar
• Boyd AE, DeFord LL, Mares JE, et al. Improving the success rate of gluteal intramuscular injections. Pancreas. 2013;42(5):878–882. doi:10.1097/MPA.0b013e318279d55223508015
   PubMed Web of Science ®Google Scholar
• Garris JL, DeFord LL, Dagohoy CG, et al. Gender related issues in gluteal intramuscular injections. Pancreas. 2010;39(2):27. doi:10.1097/01.mpa.0000363915.17360.04
   Web of Science ®Google Scholar
• Dhanda R, Varghese D, Nadipelli VR, et al. Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Prefer Adherence. 2019;13(1):1037–1050. doi:10.2147/PPA31308636
   PubMed Web of Science ®Google Scholar
• Karas A, Burdge G, Rey JA. Perseris: a new and long-acting, atypical antipsychotic drug-delivery system. Drug Forecast. 2019;44(8):460–466.
   Google Scholar
• Citrome L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (Perseris) for the treatment of Schizophrenia. New Drug Rev. 2018;1(1):130–141.
   Google Scholar
• Krogmann A, Peters L, Von Hardenberg L, Bodeker K, Nohles V, Correl C. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. Int J Neuropsychiatr Med. 2019;24(4):38–69. doi:10.1017/S109285291900124X
   Web of Science ®Google Scholar
• Andorn A, Graham J, Csernansky J, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia. Results from the phase 3 program. J Clin Psychopharmacol. 2019;39(5):428–433. doi:10.1097/JCP.000000000000107631343440
   PubMed Web of Science ®Google Scholar